UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-Q

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                   For the quarterly period ended June 30, 2010

                                       or

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

         For the transition period from ____________ to ________________

                       Commission file number: 333-139669


                                   CYTTA CORP.
             (Exact name of Registrant as specified in its charter)

            Nevada                                                98-0505761
 (State or other jurisdiction                                   (IRS Employer
of incorporation or organization)                            Identification No.)

                     905 Ventura Way, Mill Valley, CA 94941
                    (Address of principal executive offices)

                                 (415) 860-5192
              (Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  Registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of
this chapter)  during the  preceding 12 months (or for such shorter  period that
the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark whether the Registrant is a large  accelerated  filer, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
the definitions of "large accelerated filer,"  "accelerated filer," and "smaller
reporting company" in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer [ ]                       Accelerated filer [ ]

Non-accelerated filer [ ]                         Smaller reporting company [X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the  Registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of July 27th,  2010, there were  1,014,616,666  shares of the issuer's common
stock, par value $0.00001, outstanding.
<PAGE>
                         PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The accompanying unaudited financial statements have been prepared in accordance
with accounting  principles  generally  accepted in the United States of America
and the rules of the Securities and Exchange Commission  ("SEC"),  and should be
read in  conjunction  with the audited  financial  statements  and notes thereto
contained in the  Company's  September  30, 2009 Form 10-K filed with the SEC on
January 13, 2010. In the opinion of management,  all adjustments,  consisting of
normal  recurring  adjustments,  necessary for a fair  presentation of financial
position  and the  results of  operations  for the periods  presented  have been
reflected  herein.  The results of operations for the periods  presented are not
necessarily indicative of the results to be expected for the full year.

                                       2
<PAGE>
                                   CYTTA CORP.
                          (A Development Stage Company)

                          INTERIM FINANCIAL STATEMENTS

                      JUNE 30, 2010 and SEPTEMBER 30, 2009

                                   (Unaudited)

                                                                            Page
                                                                            ----

Balance Sheets as of JUNE 30, 2010 (unaudited) and September 30, 2009         4

Interim Statements of Operations for the three months and nine months
  ended June 30, 2010 and 2009 (unaudited) and for the Period from
  May 30, 2006 (inception) through June 30, 2010 (unaudited)                  5

Interim Statements of Cash Flows for the nine months ended June 30, 2010
  and 2009 (unaudited) and for the Period from May 30, 2006 (inception)
  through June 30, 2010 (unaudited)                                           6

Notes to Interim Financial Statements (unaudited)                             7

                                       3
<PAGE>
                                   Cytta Corp.
                          (A Development Stage Company)
                                 Balance Sheets

<TABLE>
<CAPTION>
                                                                      June 30,          September 30,
                                                                        2010                2009
                                                                     ---------           ---------
                                                                    (Unaudited)
<S>                                                                  <C>                 <C>
                                     ASSETS
CURRENT ASSETS
  Cash and cash equivalents                                          $   2,484           $     136
                                                                     ---------           ---------
OTHER ASSETS
  Prepaid fees and services                                            107,338                  --
                                                                     ---------           ---------
      Total Other Assets                                               107,338                  --

      TOTAL ASSETS                                                   $ 109,822           $     136
                                                                     =========           =========
                      LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
  Accounts payable and accrued liabilities                           $  11,318           $  18,052
  Due to shareholder                                                     9,268                  --
  Due to related party (Note 5)                                             --               9,388
                                                                     ---------           ---------
      TOTAL LIABILITIES                                                 20,586              27,440
                                                                     ---------           ---------
STOCKHOLDERS' DEFICIT
  Capital Stock (Note 3)
   Authorized:
     100,000,000 preferred shares, $0.001 par value
     1,900,000,000 common shares, $0.00001 par value
   Issued and outstanding shares:
     1,014,616,666 common shares                                         9,586               6,054
   Additional paid-in capital                                          407,854             199,456
   56,000,000 common shares pending cancellation                           560                 560
   Deficit accumulated during the development stage                   (328,764)           (233,374)
                                                                     ---------           ---------
      Total Stockholders' Deficit                                       89,236             (27,304)
                                                                     ---------           ---------

      TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                    $ 109,822           $     136
                                                                     =========           =========

</TABLE>

    The accompanying notes are an integral part of these financial statements

                                       4
<PAGE>
                                  Cytta Corp..
                          (A Development Stage Company)
                        Interim Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                                                         Cumulative from
                                                                                                            Inception
                                       Three Months Ended June 30,       Nine Months Ended June 30,     (May 30, 2006) to
                                     -------------------------------   -------------------------------       June 30,
                                          2010              2009           2010              2009              2010
                                     --------------     ------------   ------------     --------------     -----------
<S>                                          <C>               <C>           <C>                <C>            <C>
REVENUES                             $           --     $         --   $         --     $           --     $        --

OPERATING EXPENSES
  Professional fees                          16,605            9,836         31,927             29,058         111,416
  Management fees                            45,000               --         52,662                 --          52,662
  General and administrative                  8,747         (164,056)        10,420            222,482          47,724
  Impairment of licensing agreement              --               --             --                 --         116,581
                                     --------------     ------------   ------------     --------------     -----------
Total Operating Expenses                     70,352         (154,220)        95,009            251,540         328,383

Other Income (Expense)                         (234)              --           (381)                --         (381.00)

Provision for Income Taxes (Note 4)              --               --             --                 --              --
                                     --------------     ------------   ------------     --------------     -----------
Net Income (Loss)                    $      (70,586)    $    154,220   $    (95,390)    $     (251,540)    $  (328,764)

PER SHARE DATA:
  Basic and diluted income
  (loss) per common share            $        (0.00)    $       0.00   $      (0.00)    $        (0.00)
                                     --------------     ------------   ------------     --------------

Weighted average number of
 common shares outstanding            1,014,616,666      962,343,333    809,044,872      1,108,037,463
                                     --------------     ------------   ------------     --------------

</TABLE>

    The accompanying notes are an integral part of these financial statements

                                       5
<PAGE>
                                  Cytta Corp.
                          (A Development Stage Company)
                        Interim Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                  Cumulative from
                                                                                                     Inception
                                                                Nine Months Ended June 30,       (May 30, 2006) to
                                                              -----------------------------           June 30,
                                                                2010                2009                2010
                                                              ---------           ---------           ---------
<S>                                                           <C>                 <C>                 <C>
Cash flows from operating activities:
  Net income (loss)                                           $ (95,391)          $(251,540)          $(332,228)
  Adjustments to reconcile net income (loss) to net
   cash from operating activities:
     Depreciation and amortization                                   --                 395               3,419
     Impairment of licensing agreement                               --                  --             116,581
     Issuance of common stock for services and expenses              --                  --                  70
     Expenses paid on Company's behalf by related party          16,092                  --              16,092
     Expenses paid on Company's behalf by shareholder               568                  --                 568
  Changes in Operating Assets and Liabilities:
    Accounts payable and accrued laibilities                       (283)                (25)              9,206
    Prepaid fees and services                                    73,662                  --                  --
                                                              ---------           ---------           ---------
           Net cash from operating activities                    (5,352)           (251,170)           (186,292)
                                                              ---------           ---------           ---------
Cash flows from financing activities:
  Issuance of capital stock                                          --             209,440              86,000
  Capital stock pending cancellation                                 --                 560                  --
  Advances from shareholder                                       7,700                  --                  --
  Advances from a related party                                      --               6,770              21,414
                                                              ---------           ---------           ---------
           Net cash from financing activities                     7,700             216,770             107,414
                                                              ---------           ---------           ---------
Net change in cash                                                2,348             (34,400)            (78,878)
                                                              ---------           ---------           ---------
Cash at beginning                                                   136              34,536                  --

Cash at end                                                   $   2,484           $     136           $ (78,878)
                                                              =========           =========           =========
Supplemental Cash Flow Disclosures
  Cash paid for Interest                                      $      --           $      --           $      --
                                                              =========           =========           =========

  Cash paid for Income Taxes                                  $      --           $      --           $      --
                                                              =========           =========           =========

Non-Cash Investing and Financing Activities
  Common stock issued for fees and services                   $ 180,000           $      --           $ 180,000
                                                              =========           =========           =========

  Common stock issued for debt                                $  31,930           $      --           $  31,930
                                                              =========           =========           =========

  Common stock issued for licensing agreement                 $      --           $ 120,000           $ 120,000
                                                              =========           =========           =========

</TABLE>

   The accompanying notes are an intergral part of these financial statements

                                       6
<PAGE>
                                   CYTTA CORP.
                          NOTES TO FINANCIAL STATEMENTS
                             June 30, 2010 and 2009


NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying  financial statements have been prepared by the Company without
audit. In the opinion of management,  all adjustments (which include only normal
recurring  adjustments)  necessary  to present  fairly the  financial  position,
results of  operations,  and cash flows at June 30,  2010,  and for all  periods
presented herein, have been made.

Certain  information  and footnote  disclosures  normally  included in financial
statements prepared in accordance with accounting  principles generally accepted
in the United States of America have been condensed or omitted.  It is suggested
that  these  condensed  financial  statements  be read in  conjunction  with the
financial  statements and notes thereto included in the Company's  September 31,
2009 audited  financial  statements.  The results of  operations  for the period
ended June 30, 2010 is not necessarily  indicative of the operating  results for
the full year.

NOTE 2 - GOING CONCERN

The  Company's  financial  statements  are  prepared  using  generally  accepted
accounting  principles  in the United  States of America  applicable  to a going
concern  which  contemplates  the  realization  of  assets  and  liquidation  of
liabilities  in  the  normal  course  of  business.  The  Company  has  not  yet
established  an ongoing  source of revenues  sufficient  to cover its  operating
costs and allow it to continue as a going concern. The ability of the Company to
continue  as a going  concern is  dependent  on the Company  obtaining  adequate
capital to fund operating losses until it becomes profitable.  If the Company is
unable to obtain adequate capital, it could be forced to cease operations.

In order to continue as a going  concern,  the  Company  will need,  among other
things,  additional  capital  resources.  Management's  plan is to  obtain  such
resources for the Company by obtaining  capital from  management and significant
shareholders  sufficient  to meet its  minimal  operating  expenses  and seeking
equity and/or debt financing.  However  management cannot provide any assurances
that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent  upon its
ability  to  successfully  accomplish  the  plans  described  in  the  preceding
paragraph and eventually secure other sources of financing and attain profitable
operations. The accompanying financial statements do not include any adjustments
that might be necessary if the Company is unable to continue as a going concern.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States of America requires  management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities at the date of the financial  statements and the reported amounts of
revenue and expenses  during the reporting  period.  Actual results could differ
from those estimates.

                                       7
<PAGE>
                                   CYTTA CORP.
                          NOTES TO FINANCIAL STATEMENTS
                             June 30, 2010 and 2009


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

RECENT ACCOUNTING PRONOUNCEMENTS

Below is a listing of the most recent accounting pronouncements issued since the
September 31, 2009 audited financial statements of the Company were released and
through July 28, 2010. The Company has evaluated these  pronouncements  and does
not expect their adoption to have a material  impact on the Company's  financial
position, or statements.

*    Accounting Standards Update 2010-17 Revenue  Recognition-  Milestone Method
     (Topic 605):  Milestone Method of Revenue  Recognition - a consensus of the
     FASB  emerging  issues task force.  Effective  for fiscal years on or after
     June 15, 2010.
*    Accounting  Standards  Update 2010-12 Income Taxes (Topic 740):  Accounting
     for Certain  Tax Effects of the 2010 Health Care Reform Acts (SEC  Update).
     Effective July 1, 2010.
*    Accounting  Standards  Update  2010-11Derivatives  and Hedging (Topic 815):
     Scope Exception Related to Embedded Credit  Derivatives.  Effective July 1,
     2010.
*    Accounting   Standards  Update  2010-09   Subsequent  Events  (topic  855):
     Amendments to Certain  Recognition and Disclosure  Requirements.  Effective
     July 1, 2010.
*    Accounting Standards Update 2010-06 Fair Value Measurements and Disclosures
     (Topic 820): Improving Disclosures about Fair Value Measurements. Effective
     July 1, 2010.
*    Accounting   Standards  Update  2010-05   Compensation-Stock   Compensation
     (Topic718): Escrowed share arrangements and the Presumption of Compensation
     (SEC Update). Effective July 1, 2010.
*    Accounting  Standards Update 2010-04 (ASU 2010-04),  Accounting for Various
     Topics-Technical Corrections to SEC Paragraphs. Effective July 1, 2010.

NOTE 3 - RELATED PARTY NOTES PAYABLE

As of June 30, 2010 and September 31, 2009,  the Company had borrowed a total of
$-0- and  $9,338  from  related  parties.  These  notes  bear no  interest,  are
unsecured and are due on demand.

NOTE 4 - DUE TO SHAREHOLDER

As of June 30, 2010 and September 31, 2009 the Company owed a shareholder $9,268
and $-0- on an unsecured note that bears no interest and is due on demand

NOTE 5 - SUBSEQUENT EVENTS

The Company has evaluated  subsequent events from the balance sheet date through
the date of this report. There have been no reportable subsequent events.

                                       8
<PAGE>
ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

FORWARD-LOOKING STATEMENTS

Except  for  historical  information,   this  report  contains   forward-looking
statements  within the meaning of Section 27A of the  Securities Act of 1933 and
Section  21E of  the  Securities  Exchange  Act of  1934.  Such  forward-looking
statements  involve  risks and  uncertainties,  including,  among other  things,
statements  regarding our business  strategy,  future  revenues and  anticipated
costs and expenses. Such forward-looking statements include, among others, those
statements including the words "expects,"  "anticipates,"  "intends," "believes"
and similar  language.  Our actual results may differ  significantly  from those
projected  in the  forward-looking  statements.  Factors  that  might  cause  or
contribute to such differences  include, but are not limited to, those discussed
herein as well as in the "Description of Business - Risk Factors" section in our
Annual  Report on Form 10-K for the year ended  September  30, 2009.  You should
carefully review the risks described in our Annual Report and in other documents
we file from time to time with the Securities and Exchange  Commission.  You are
cautioned not to place undue reliance on the forward-looking  statements,  which
speak only as of the date of this report. We undertake no obligation to publicly
release any revisions to the  forward-looking  statements  or reflect  events or
circumstances after the date of this document.

Although we believe that the  expectations  reflected  in these  forward-looking
statements are based on reasonable assumptions,  there are a number of risks and
uncertainties  that could cause actual  results to differ  materially  from such
forward-looking statements.

All references in this Form 10-Q to the "Company," "Cytta," "we," "us," or "our"
are to Cytta Corp.

RESULTS OF OPERATIONS

We are a development stage  corporation.  We have generated no revenues from our
business operations since inception (May 30, 2006) and have incurred $328,383 in
expenses through June 30, 2010.

The following  table  provides  selected  financial data about our company as of
June 30, 2010 and September 30th, 2009, respectively.

Balance Sheet Data                 June 30, 2010        September 30, 2009
------------------                 -------------        ------------------
Cash and cash equivalents             $  2,484                 $    136
Total Assets                          $109,822                 $    136
Total Liabilities                     $ 20,586                 $ 27,440
Shareholder Equity (Deficit)          $ 89,236                 $(27,304)

Net cash used by operating  activities  since  inception  (May 30, 2006) through
June 30, 2010 was $185,292.

                                       9
<PAGE>
PLAN OF OPERATION

On June  18th,  2009,  the  Company  entered  into a  Licensing  Agreement  with
Lifespan,  Inc.  Through  a series of  transactions  and  business  developments
commencing  in 2002,  Lifespan  had  acquired  the  expertise  and  licenses  to
manufacture,  distribute and market  various  technology-based  internet  access
products and services,  consisting of internet access devices,  related software
and hardware and a series of medical peripherals designed and adapted to provide
remote  monitoring  of patients.  The Company has been  utilizing the License to
develop a healthcare  model for the internet  access  devices and utilized  this
knowledge and expertise in entering into the Value Added Reseller agreement with
MedApps Inc.

On June 12th,  2010,  the  Company  entered  into a Value Added  Reseller  (VAR)
Agreement with MedApps Inc. ("MedApps"). The terms of the agreement provide that
Cytta Corp. will be a non-exclusive  value added reseller of MedApps  propietary
`Medical Remote Patient Monitoring  System' products in California,  Nevada, and
Arizona and Canada (excluding Quebec).  Additional territories may be negotiated
directly between the parties based upon mutual interest.

The Company will be negotiating  cash and share  consideration  to MedApps based
upon the ultimate  product  costing  structure  negotiated  between the parties.
Cytta  Corp.   and  its  agents   will  be   providing   comprehensive   systems
implementation  and integration of the MedApps  proprietary  medical  monitoring
technology  in the  Medical  Home.  Cytta  and  its  agents  will  be  primarily
concentrating  on clients  consisting of payors and  providers,  such as: Health
Plans, Managed Care Organizations, Health Delivery Organizations, Medical Groups
and IPAs.  Cytta and MedApps are currently  working together to develop seamless
integration  models  designed  to meet  the  needs  of  particular  clients.  An
integrated  rollout  plan  will be  developed  as well as a  series  of  unified
presentations.

The  MedApps   Remote   Patient   Monitoring   system   (further   described  at
www.medapps.com) supports the desire for simplicity of setup/use - and the power
of medical data  management  by healthcare  providers.  There is no need for the
user to1) push ANY  buttons,  2) to operate a personal  computer,  3) write down
readings or 4) to be tech savvy to obtain their medical records in any way.

MedApps provides  solutions to several aspects of healthcare  programs involving
the  retrieval,  logging,  analysis,  tracking,  alerting and report  writing of
medical data:

*    Near  real  time  customer  risk  assessment  is  much  easier  due  to the
     efficiency of obtaining medical data electronically. Data is presented in a
     timely fashion in an orderly format.
*    Risk assessment over time is much easier to monitor due to more useful data
     being received with  time-stamped  trend  analysis,  threshold  setting and
     alert notification when critical control limits are violated.
*    Reduced  risk is realized  due to the  opportunity  for better  health care
     decisions based on treatment effect adjustments from data trend analysis.

                                       10
<PAGE>
This  MedApps  Remote  Patient  Monitoring  System  provides the  following  key
features:

*    The  MedApps   HealthPAL  MA-106  is  the  data   aggregator.   This  is  a
     Bluetooth/Cell - enabled medical  monitoring  device. A USB  wire/connector
     can be utilized with this device. The device can be charged directly.
*    The  MedApps  HealthHUB  MA206  can  be  added  to  the  configuration  for
     utilization  as a  charging  port and  additional  USB  connection  hub for
     medical device connectivity to the HealthPAL interface.
*    MedApps'  kits  are  scalable  and  can be used to  support  patients  with
     Diabetes,   Hypertension,   Congestive  Heart  Failure,   CAD  and  Chronic
     Obstructive Pulmonary Disease in the future by adding the necessary medical
     monitoring.
*    The  MedApps  HealthCOM  system  can  be  the  repository  for  data  to be
     integrated  into other health record  systems,  such as NextGen,  Microsoft
     HealthVault, Google Health, EPIC, SPINN, Allscripts and Eclipsys.
*    Customers  may choose to  provide  the  approved  medical  devices  and the
     personnel for the monitoring service for user interface.

The MedApps'  Remote Patient  Monitoring  system is FDA approved,  FCC approved,
ISO13485 certified, AT&T certified, Verizon certified and IEEE1725 certified.

THE MEDAPPS' HEALTHPAL MA106

The MedApps health  monitoring system was designed for easy set-up and operation
of the data accumulation (via HealthPAL) segment.

*    MedApps  focused  upon  the  ease of  setting  up and  operation  of  their
     HealthPAL products.
*    The  HealthPAL  is updated on new  firmware  revisions  in the field  using
     Firmware Over the Air (FOTA)  technology.  These updates are performed late
     at night / early  morning  for the  given  time  zone to  allow  continuous
     operation  during  typical  active  ("awake")  hours.   This  occurs  after
     receiving approval from the customer.
*    Customer  support is provided by MedApps'  customer support to troubleshoot
     any issues that may arise while operating the  HealthPAL/HealthCOM  system.
     This is especially  important during the early deployment / start-up period
     with new customers that are not familiar with MedApps products.

                                       11
<PAGE>
THE MEDAPPS' HEALTHCOM SYSTEM

The health  monitoring  system was designed for easy set up and operation of the
data  analysis (via  HealthCOM)  segment.  Included in the software  designs are
several features that allow customers to:

*    Easily set up and change user assignments and details.
*    Provide user  friendly  screens with clear data fields and color - actuated
     cells for custom user features.
*    Set primary and secondary  thresholds  for "early  warning" and  "critical"
     alerts.
*    Automated  alerts to the authorized care provider when critical  thresholds
     have been violated.
*    Create time stamped trend snapshots.
*    Generate useful user reports for easy data review.

MEDAPPS SUPPORTS ALL EHR/PHR/EMR SYSTEMS

MedApps  supports  connectivity to various  EHR/PHR/EMR  systems and is ready to
support  these  systems on any of the options  available.  MedApps can currently
send data to a variety of enterprise  level EHRs,  for example,  EPIC,  NextGen,
Allscripts,  Microsoft  HealthVault  and  Google  Health.  MedApps is capable of
sending data to specific EMRs designated by the customer.

PRODUCTS AND SERVICES ARE FULLY SCALABLE AND DESIGNED TO ALLOW RAPID GROWTH

MedApps  product  assembly,  electrical  test and functional  test processes are
performed  in an ISO 13485  and ISO 9001  certified  facility  in  Arizona.  All
processes are fully documented and have been audited.  The firmware and software
architecture has been specifically  designed for scalability to allow additional
server capacity as needed.

PRICING AND DELIVERY

Delivery is currently  eight to ten weeks from date of purchase with future lead
times based on forecast inputs. Several innovative pricing models are offered.

Cytta currently has minimal operating costs and expenses at the present time due
to our relatively new business activities.  However we anticipate  significantly
increasing our  activities as a result of the License  Agreement and Value Added
Reseller  Agreement.  We have  entered into certain  management  and  consulting
contracts with our senior  Officers and non affiliated  consultants  who will be

                                       12
<PAGE>
providing   business   services  to  the  Company  in  the  health  care  arena.
Additionally,  we will be required to raise  significant  capital  over the next
twelve months,  in connection  with our operations  resulting from our marketing
Agreements.  We do not currently  engage in any product research and development
however the Company's  marketing  Agreements  may cause us to engage in research
and development in the foreseeable  future. We have no present plans to purchase
or sell any plant or significant equipment although we will have to acquire some
equipment related to the marketing  Agreements.  We also have no immediate plans
to add employees, other than the current management and consultants, although we
may do so in the future as a result of the  operations  related to the marketing
Agreements.

LIQUIDITY AND CAPITAL RESOURCES

Our cash and cash equivalents balance as of June 30, 2010 was $2,484.

We  are a  development  stage  company  and  currently  have  limited  marketing
operations.

We do not have  sufficient  funds on hand to pursue our business  objectives for
the near future or to commence full scale operations  without seeking additional
funding.  We  currently  do not have a specific  plan of how we will obtain such
funding.

LOANS TO THE COMPANY

We have been  receiving  loans from  shareholders  of the company to pay general
operating costs. As of June 30, 2010, we had $9,268 in loans outstanding.

We have  minimal  operating  costs and  expenses at the present  time due to our
limited  business   activities.   Currently  our  operating  activities  in  the
healthcare  arena are conducted by our senior Officers and engaged  consultants.
We will,  however,  be required to raise additional capital over the next twelve
months  to  meet  our  current  administrative   expenses  and  to  develop  our
operations.  This financing may take the form of additional  sales of our equity
or debt  securities  to, or loans from,  stockholders,  or from our officers and
directors or other individuals.  There is no assurance that additional financing
will be available from these or other sources, or, if available, that it will be
on terms favorable to us.

GOING CONCERN

Our  auditors  have  included an  explanatory  paragraph  in their report on our
financial  statements  relating to the  uncertainty  of our  business as a going
concern,   due  to  our  limited  operating  history,  our  lack  of  historical
profitability,  and our limited funds.  We believe that we will be able to raise
the required funds for operations and to achieve our business plan.

OFF-BALANCE SHEET ARRANGEMENTS

We have never entered into any off-balance sheet financing arrangements and have
not formed any special  purpose  entities.  We have not  guaranteed  any debt or
commitments  of other  entities  or entered  into any  options on  non-financial
assets.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

                                       13
<PAGE>
ITEM 4T. CONTROLS AND PROCEDURES

EVALUATION OF OUR DISCLOSURE CONTROLS

Under the  supervision  and with the  participation  of our  senior  management,
including  our chief  executive  officer and chief  financial  officer,  Stephen
Spalding,  we conducted an  evaluation  of the  effectiveness  of the design and
operation  of our  disclosure  controls  and  procedures,  as  defined  in Rules
13a-15(e) and 15d-15(e)  under the  Securities  Exchange Act of 1934, as amended
(the  "Exchange  Act"),  as of the end of the period  covered by this  quarterly
report (the "Evaluation  Date").  Based on this evaluation,  our chief executive
officer and chief financial officer concluded as of the Evaluation Date that our
disclosure  controls and procedures  were  effective  such that the  information
relating  to us,  required  to be  disclosed  in  our  Securities  and  Exchange
Commission ("SEC") reports (i) is recorded,  processed,  summarized and reported
within  the  time  periods  specified  in SEC  rules  and  forms,  and  (ii)  is
accumulated and  communicated  to our management,  including our chief executive
officer and chief financial  officer,  as appropriate to allow timely  decisions
regarding required disclosure.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting that
occurred during the quarter ended June 30, 2010 that have materially affected or
are reasonably  likely to materially  affect our internal control over financial
reporting.

                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of our business,  we may from time to time become subject
to routine litigation or administrative  proceedings which are incidental to our
business.  We are not a party to nor are we aware of any  existing,  pending  or
threatened lawsuits or other legal actions involving us.

ITEM 1A. RISK FACTORS

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

On June 12th,  2010,  the  Company  entered  into a Value Added  Reseller  (VAR)
Agreement with MedApps Inc.  ("MedApps")  attached  hereto as an Exhibit 10. The
terms of the agreement  provide that Cytta Corp. will be a  non-exclusive  value
added reseller of MedApps `Medical Remote Patient Monitoring System' products in
California,  Nevada, and Arizona and Canada (excluding  Quebec).  Details of the
MedApps proprietary  `Medical Remote Patient Monitoring System' are described in
ITEM 2 Plan of Operation and at www.medapps.com.

                                       14
<PAGE>
ITEM 6. EXHIBITS

The following exhibits are included as part of this report:

Exhibit No.                      Description
-----------                      -----------

10               MedApps/ Cytta VAR Agreement dated June 12th, 2010

31.1 / 31.2      Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal
                 Executive and Financial Officer

32.1 / 32.2      Rule 1350 Certification of Principal Executive and Financial
                 Officer

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

CYTTA CORP.

Dated: June 27th, 2010


By: /s/ Stephen Spalding
    ----------------------------------------------
    Stephen Spalding
    CEO, Principal Executive and Financial Officer